The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1942
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review ; day:9 ; month:1 ; year:2018 ; pages:1-16
Drug safety ; (9.1.2018), 1-16
- Schlagwort
-
Kardiovaskuläre Krankheit
- Urheber
-
Nurmohamed, Michael
- Beteiligte Personen und Organisationen
-
Choy, Ernest
Lula, Sadiq
Kola, Blerina
DeMasi, Ryan
Accossato, Paola
SpringerLink (Online service)
- DOI
-
10.1007/s40264-017-0628-9
- URN
-
urn:nbn:de:1111-201803013902
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nurmohamed, Michael
- Choy, Ernest
- Lula, Sadiq
- Kola, Blerina
- DeMasi, Ryan
- Accossato, Paola
- SpringerLink (Online service)
Ähnliche Objekte (12)
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Biologics, cardiovascular effects and cancer
Editorial: Methods in cardiovascular biologics and regenerative medicine
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rheumatic diseases and obesity: adipocytokines as potential comorbidity biomarkers for cardiovascular diseases
Rheumatic diseases and sport
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review
Biologics in therapy
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Biologics, cardiovascular effects and cancer
Editorial: Methods in cardiovascular biologics and regenerative medicine
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rheumatic diseases and obesity: adipocytokines as potential comorbidity biomarkers for cardiovascular diseases
Rheumatic diseases and sport
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review
Biologics in therapy
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Biologics, cardiovascular effects and cancer
Editorial: Methods in cardiovascular biologics and regenerative medicine
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rheumatic diseases and obesity: adipocytokines as potential comorbidity biomarkers for cardiovascular diseases
Rheumatic diseases and sport
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review